2025-12-23 - Analysis Report
Okay, here's a comprehensive analysis of Johnson & Johnson (JNJ) based on the data provided.

**0. Introduction:**

This report analyzes the current state of Johnson & Johnson (JNJ) stock, comparing it to the S&P 500 (VOO), examining its financial performance, technical indicators, recent news, and analyst opinions to provide an informed overview.

**1. Return Rate Comparison and Divergence:**

*   **Company Overview:** Johnson & Johnson (JNJ) is a multinational corporation that develops and manufactures pharmaceuticals, medical devices, and consumer packaged goods.
*   **JNJ Cumulative Return:** 59.05%
*   **VOO Cumulative Return:** 100.88%
*   **Divergence:** -41.8% (Current)
*   **Relative Divergence:** 28.9%

**Analysis:** JNJ has significantly underperformed the S&P 500 over the period analyzed. The current divergence of -41.8% indicates a substantial difference in cumulative returns. The relative divergence of 28.9% suggests that the current divergence is closer to the lower end of its historical range.

**Alpha, Beta Analysis:**

| Year       | CAGR  | MDD   | Alpha | Beta | Cap(B) |
|------------|-------|-------|-------|------|--------|
| 2015-2017  | 26.0% | 66.8% | -2.0% | -0.1 | 338.2  |
| 2016-2018  | 14.0% | 10.7% | -1.0% | 0.1  | 312.4  |
| 2017-2019  | 20.0% | 71.5% | -2.0% | 0.4  | 353.1  |
| 2018-2020  | 19.0% | 79.2% | -4.0% | 0.4  | 380.9  |
| 2019-2021  | 33.0% | 79.2% | -14.0% | 0.5  | 414.1  |
| 2020-2022  | 8.0%  | 79.6% | 9.0%  | 0.4  | 427.6  |
| 2021-2023  | -19.0% | 79.6% | -20.0% | 0.3  | 379.4  |
| 2022-2024  | -32.0% | 79.6% | -53.0% | 0.3  | 350.0  |
| 2023-2025  | 30.0%  | 79.6% | -35.0% | 0.1  | 499.5  |

**Analysis:** The Alpha values are mostly negative, indicating underperformance relative to its benchmark (likely the S&P 500) for most periods. The Beta values are generally low (between 0.1 and 0.5), suggesting JNJ has been less volatile than the market. The negative Alpha combined with a relatively low Beta suggests that JNJ may not be generating excess returns for the level of risk it carries. The Maximum Drawdown (MDD) has been quite high in recent years, indicating significant potential losses from peak to trough. CAGR figures were very high in 2015-2021 but performance has weakened in 2021-2025.

**2. Recent Stock Price Fluctuations:**

*   **Current Price:** 206.37
*   **Last Market Data:** Price: 207.32, Previous Close: 206.37, Change: 0.46
*   **5-day SMA:** 209.70
*   **20-day SMA:** 206.46
*   **60-day SMA:** 195.83

**Analysis:** The stock is currently trading above its 20-day and 60-day Simple Moving Averages (SMAs), but below its 5-day SMA.  This suggests a short-term pullback after a recent upward trend. The fact that the 20-day SMA is above the 60-day SMA implies an overall upward trend in the medium term.

**3. Technical Indicators:**

*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment)
*   **RSI:** 53.23 (Neutral)
*   **PPO:** -0.19
*   **Hybrid Signal:** cash_0%_Buy 90% of cash (1 shares - Safe - MRI:0.80)
*   **Recent (20 days) Relative Divergence Change:** -5.1 (Negative - Short-term decline)
*   **Expected Return (%):** -59.0%

**Analysis:** The MRI suggests a medium investment recommendation. The RSI is near the middle (50), indicating a neutral momentum. The negative PPO suggests that the shorter-term moving average is below the longer-term moving average, indicating a potential downtrend. The Hybrid signal suggests buying with a high cash allocation, indicating a safety-first approach. The recent negative change in relative divergence confirms a short-term decline. The expected return is very bad, suggesting negative long-term returns compared to S&P 500.

**4. Recent News & Significant Events:**

*   **Positive:** Multiple articles highlight J&J stock trading above its 50-day and 200-day SMAs, which is generally seen as a bullish signal. Wedge Capital Management increased its holdings in JNJ. An article in The Motley Fool points to a reason for the stock's surge this month.
*   **Neutral/Mixed:** Articles discussing FDA catalysts, talc litigation, analyst targets, and potential factors influencing the stock.
*   **Key Takeaways:** The news is a mixed bag. The articles highlight positive technical indicators and increased investment, but also potential risks related to litigation and regulatory events.

**4-2. Analyst Opinions:**

*   **Consensus:** Buy (Mean: 2.16)
*   **Target Price:** Average: 209.29, High: 240.00, Low: 155.00

**Analysis:** The analyst consensus is "Buy" with an average target price slightly above the current price. However, the wide range between the high and low target prices indicates considerable uncertainty among analysts.

**5. Recent Earnings Analysis:**

| 날짜       | EPS  | 매출       |
|------------|------|------------|
| 2025-10-22 | 2.14 | 23.99 B$   |
| 2025-07-24 | 2.3  | 23.74 B$   |
| 2025-04-23 | 4.57 | 21.89 B$   |
| 2024-10-23 | 1.12 | 22.47 B$   |
| 2025-10-22 | 1.12 | 22.47 B$   |

**Analysis:** Revenue has been relatively stable in recent quarters, with some fluctuation. EPS has varied more significantly, particularly with the 4.57 figure in April 2025. The repeated value on the last line (2025-10-22) raises a possible data duplication error.

**6. Financial Information:**

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-09-30   | $23.99B   | 69.56%        |
| 2025-06-30   | $23.74B   | 67.87%        |
| 2025-03-31   | $21.89B   | 66.40%        |
| 2024-12-31   | $22.52B   | 68.35%        |
| 2024-09-30   | $22.47B   | 69.01%        |

**Capital and Profitability:**

| Quarter      | Equity    | ROE   |
|--------------|-----------|-------|
| 2025-09-30   | $79.28B   | 6.50% |
| 2025-06-30   | $78.47B   | 7.06% |
| 2025-03-31   | $78.11B   | 14.08% |
| 2024-12-31   | $71.49B   | 4.80% |
| 2024-09-30   | $70.16B   | 3.84% |

**Analysis:** Revenue has shown a general upward trend. Profit margins are consistently high. Equity has increased over the past year, but ROE has fluctuated significantly, reaching a peak in March 2025 and then declining.

**7. Comprehensive Analysis (Summary):**

Johnson & Johnson (JNJ) presents a mixed picture. While the company has a strong financial position (high profit margins, increasing equity, stable revenue), its stock performance has lagged the S&P 500 significantly. Technical indicators are neutral to slightly bearish, suggesting potential short-term weakness. Analyst opinions are generally positive, but with considerable uncertainty. Recent news highlights both positive technical factors and potential risks related to litigation and regulatory issues. The large negative expected return compared to S&P 500 is worrying.

**Conclusion:**

JNJ appears to be a fundamentally sound company, but the stock faces headwinds. Investors should weigh the company's strong financials and analyst recommendations against its recent underperformance, negative expected return and potential risks before making a decision.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.